<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Broeck, M. van den</title>
    <link>http://repub.eur.nl/res/aut/6753/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Linkage and association studies identify a novel locus for Alzheimer disease at 7q36 in a Dutch population-based sample (Article)</title>
      <link>http://repub.eur.nl/res/pub/8490/</link>
      <pubDate>2005-01-01T00:00:00Z</pubDate>
      <description>We obtained conclusive linkage of Alzheimer disease (AD) with a candidate region of 19.7 cM at 7q36 in an extended multiplex family, family 1270, ascertained in a population-based study of early-onset AD in the northern Netherlands. Single-nucleotide polymorphism and haplotype association analyses of a Dutch patient-control sample further supported the linkage at 7q36. In addition, we identified a shared haplotype at 7q36 between family 1270 and three of six multiplex AD-affected families from the same geographical region, which is indicative of a founder effect and defines a priority region of 9.3 cM. Mutation analysis of coding exons of 29 candidate genes identified one linked synonymous mutation, g.38030G--&gt;C in exon 10, that affected codon 626 of the PAX transactivation domain interacting protein gene (PAXIP1). It remains to be determined whether PAXIP1 has a functional role in the expression of AD in family 1270 or whether another mutation at this locus explains the observed linkage and sharing. Together, our linkage data from the informative family 1270 and the association data in the population-based early-onset AD patient-control sample strongly support the identification of a novel AD locus at 7q36 and re-emphasize the genetic heterogeneity of AD.</description>
    </item> <item>
      <title>Absence of pathogenic mutations in presenilin homologue 2 in a conclusively 17-linked tau-negative dementia family (Letter To Editor)</title>
      <link>http://repub.eur.nl/res/pub/5894/</link>
      <pubDate>2004-02-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Early cognitive decline is associated with prion protein codon 129 polymorphism (Letter To Editor)</title>
      <link>http://repub.eur.nl/res/pub/5865/</link>
      <pubDate>2003-08-01T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample (Article)</title>
      <link>http://repub.eur.nl/res/pub/8503/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>Nicastrin regulates gamma-secretase cleavage of the amyloid precursor protein by forming complexes with presenilins, in which most mutations causing familial early-onset Alzheimer disease (EOAD) have been found. The gene encoding nicastrin (NCSTN) maps to 1q23, a region that has been linked and associated with late-onset Alzheimer disease (LOAD) in various genome screens. In 78 familial EOAD cases, we found 14 NCSTN single-nucleotide polymorphisms (SNPs): 10 intronic SNPs, 3 silent mutations, and 1 missense mutation (N417Y). N417Y is unlikely to be pathogenic, since it did not alter amyloid beta secretion in an in vitro assay and its frequency was similar in case and control subjects. However, SNP haplotype estimation in two population-based series of Dutch patients with EOAD (n=116) and LOAD (n=240) indicated that the frequency of one SNP haplotype (HapB) was higher in the group with familial EOAD (7%), compared with the LOAD group (3%) and control group (3%). In patients with familial EOAD without the APOE epsilon4 allele, the HapB frequency further increased, to 14%, resulting in a fourfold increased risk (odds ratio = 4.1; 95% confidence interval 1.2-13.3; P=.01). These results are compatible with an important role of gamma-secretase dysfunction in the etiology of familial EOAD.</description>
    </item> <item>
      <title>Amyloid beta secretase gene (BACE) is neither mutated in nor associated with early-onset Alzheimer's disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/5851/</link>
      <pubDate>2001-11-02T00:00:00Z</pubDate>
      <description>The beta-site of beta-amyloid precursor protein cleaving enzyme (BACE) cleaves the beta-amyloid (Abeta) precursor protein at the N-terminal end of Abeta, allowing for the production of Abeta by C-terminal gamma-secretase cleavage. We hypothesized that over-activity of BACE might lead to the overproduction of Abeta, hence causing Alzheimer's disease (AD). Molecular genetic analyses of BACE in 9 autosomal dominant AD families and a population-based sample of 101 presenile AD cases did not identify genetic linkage, pathogenic mutations or genetic association with BACE, suggesting that BACE is not genetically involved in the etiology of AD</description>
    </item> <item>
      <title>Genetic variability in the regulatory region of presenilin 1 associated with risk for Alzheimer's disease and variable expression (Article)</title>
      <link>http://repub.eur.nl/res/pub/9244/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Mutations in the presenilin 1 ( PSEN1 ) gene have been implicated in
      18-50% of autosomal dominant cases with early-onset Alzheimer's disease
      (EOAD). Also, PSEN1 has been suggested as a potential risk gene in
      late-onset AD cases. We recently showed genetic association in a
      population-based study of EOAD, pointing to the 5' regulatory region of
      PSEN1. In this study we systematically screened 3.5 kb of the PSEN1
      upstream region and found four novel polymorphisms. Genetic analysis
      confirmed association of two polymorphisms with increased risk for EOAD.
      In addition, we detected two different mutations in EOAD cases at-280
      and-2818 relative to the transcription initiation site in exon 1A of
      PSEN1. Analysis of the mutant and wild-type-280 variants using luciferase
      reporter gene expression in transiently transfected neuroblastoma cells
      showed a 30% decrease in transcriptional activity for the mutant-280G
      PSEN1 promoter variant compared with the wild-type variant-280C. Our data
      suggest that the increased risk for EOAD associated with PSEN1 may result
      from genetic variations in the regulatory region leading to altered
      expression levels of the PSEN1 protein.</description>
    </item> <item>
      <title>Mutation screening of the tau gene in patients with early-onset Alzheimer's disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/5838/</link>
      <pubDate>1999-12-24T00:00:00Z</pubDate>
      <description>Hyperphosphorylated microtubule associated protein tau, present in neurofibrillary tangles, is a prominent pathological feature of Alzheimer's disease (AD). The gene encoding tau (MAPT) was recently found mutated in frontotemporal dementia (FTD) and other tauopathies. We studied MAPT as a candidate gene in the etiology of AD. The study population consisted of 101 early-onset AD patients and 117 controls. Mutation analysis did not detect causal mutations in exons 9 to 13 encoding the microtubule-binding domains involved in FTD, however, two novel polymorphisms were detected in exon 9. Using the Ala169 polymorphism in exon 9 and a previously reported (CA)n-repeat polymorphism in intron 9, an association study was performed. No association with early-onset AD was detected. Together, our data indicate that MAPT does not play a role in early-onset AD.</description>
    </item> <item>
      <title>Genetic association of the presenilin-1 regulatory region with early-onset Alzheimer's disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/5835/</link>
      <pubDate>1999-10-01T00:00:00Z</pubDate>
      <description>Genetic association has been reported between a di-allelic polymorphism in intron 8 of presenilin-1 (PSEN1) and Alzheimer's disease (AD) in some studies but not in others. In a population-based series of 102 patients with early onset AD and 118 community controls we examined whether polymorphisms in linkage disequilibrium with intron8 of PSEN1 may explain the association. In addition to the intron 8 polymorphism (P = 0.05), a promoter polymorphism (P = 0.03) and the simple tandem repeat (STR) polymorphism D14S1028 located upstream of PSEN1 (P = 0.04) were found to be marginally significantly associated to AD. When excluding PSEN1 mutation cases (n = 6), the intron 8 association was explained by linkage disequilibrium to the dominant PSEN1 mutations. In the non-mutation cases, the weak associations between the polymorphisms in the regulatory region remained. Our study suggests that a polymorphism/mutation in the promoter or regulatory region of PSEN1 rather than the polymorphism in intron 8 of PSEN1 is associated with early onset AD.</description>
    </item> <item>
      <title>Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease (Article)</title>
      <link>http://repub.eur.nl/res/pub/8752/</link>
      <pubDate>1998-01-01T00:00:00Z</pubDate>
      <description>Two closely related genes, the presenilins ( PS ), located at chromosomes
      14q24.3 and 1q42.1, have been identified for autosomal dominant Alzheimer
      disease (AD) with onset age below 65 years (presenile AD). We performed a
      systematic mutation analysis of all coding and 5'-non-coding exons of PS
      -1 and PS -2 in a population-based epidemiological series of 101 unrelated
      familial and sporadic presenile AD cases. The familial cases included 10
      patients of autosomal dominant AD families sampled for linkage analysis
      studies. In all patients mutations in the amyloid precursor protein gene (
      APP ) had previously been excluded. Four different PS -1 missense
      mutations were identified in six familial cases, two of which where
      autosomal dominant cases. Three mutations resulted in onset ages above 55
      years, with one segregating in an autosomal dominant family with mean
      onset age 64 years (range 50-78 years). One PS -2 mutation was identified
      in a sporadic case with onset age 62 years. Our mutation data provided
      estimates for PS -1 and PS -2 mutation frequencies in presenile AD of 6
      and 1% respectively. When family history was accounted for mutation
      frequencies for PS -1 were 9% in familial cases and 18% in autosomal
      dominant cases. Further, polymorphisms were detected in the promoter and
      the 5'-non-coding region of PS -1 and in intronic and exonic sequences of
      PS -2 that will be useful in genetic association studies.</description>
    </item>
  </channel>
</rss>